| Immune checkpoint association |
| durvalumab plus tremelimumab | nivolumab plus ipilimumab | pembrolizumab plus ipilimumab |
| mNSCLC - L1 - PDL1 positive 14 | | | |
Comparator:
vs Standard of Care (SoC); vs pemetrexed plus platin; vs pembrolizumab plus placebo;
Risk of bias:
low;
some concerns;
high;
NA;